Merlin L Robb Selected Research

Biomarkers (Surrogate Marker)

9/2022	Dissecting drivers of immune activation in chronic HIV-1 infection.
12/2020	Preferential Infection of α4β7+ Memory CD4+ T Cells During Early Acute Human Immunodeficiency Virus Type 1 Infection.
12/2020	RV144 HIV-1 vaccination impacts post-infection antibody responses.
1/2020	Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection.
10/2019	Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.
1/2019	Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus-Infected Kenyans.
1/2018	Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size.
1/2017	Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.
1/2017	Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection.
5/2016	Brief Report: Differential Associations of Interleukin 6 and Intestinal Fatty Acid-Binding Protein With Progressive Untreated HIV-1 Infection in Rakai, Uganda.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Merlin L Robb Research Topics

Disease

93	Infections 04/2024 - 10/2002
45	HIV Infections (HIV Infection) 10/2022 - 11/2002
14	Viremia 10/2021 - 01/2014
12	Disease Progression 10/2022 - 11/2010
10	Vaccinia 01/2023 - 11/2010
10	Inflammation (Inflammations) 10/2021 - 01/2016
9	COVID-19 11/2023 - 10/2021
7	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2023 - 04/2010
4	Breakthrough Infections 01/2021 - 09/2002
4	Virus Diseases (Viral Diseases) 01/2020 - 08/2014
4	Acquired Immunodeficiency Syndrome (AIDS) 11/2019 - 01/2017
3	Coinfection 09/2022 - 01/2019
3	Persistent Infection 12/2018 - 04/2017
3	HIV Seropositivity 01/2018 - 04/2010
2	Bites and Stings (Sting) 10/2021 - 11/2017
2	Dengue (Dengue Fever) 01/2020 - 01/2015
1	Injection Site Reaction 11/2023
1	Malaria 11/2022
1	Noncommunicable Diseases 09/2022
1	Belonephobia 01/2021
1	Fatigue 01/2021
1	Hearing Loss (Hearing Impairment) 01/2021
1	Hepatitis B 01/2021
1	Dysbiosis 12/2020
1	Fever (Fevers) 03/2019
1	Zika Virus Infection 10/2018

Drug/Important Bio-Agent (IBA)

70	VaccinesIBA 04/2024 - 09/2002
23	AntibodiesIBA 01/2023 - 01/2011
15	Immunoglobulin G (IgG)IBA 03/2023 - 04/2012
11	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2016
10	Proteins (Proteins, Gene)FDA Link 04/2024 - 11/2002
10	Biomarkers (Surrogate Marker)IBA 09/2022 - 05/2016
10	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 08/2014
10	Immunoglobulin A (IgA)IBA 12/2020 - 04/2012
9	AIDS VaccinesIBA 01/2023 - 04/2011
9	AntigensIBA 01/2022 - 11/2002
6	Neutralizing AntibodiesIBA 03/2023 - 01/2013
6	Broadly Neutralizing AntibodiesIBA 01/2022 - 05/2015
5	CytokinesIBA 01/2021 - 06/2014
5	Antiviral Agents (Antivirals)IBA 10/2019 - 07/2014
5	AIDSVAXIBA 01/2018 - 12/2009
4	ChAdOx1 nCoV-19IBA 03/2023 - 12/2021
4	Interleukin-6 (Interleukin 6)IBA 10/2019 - 04/2011
4	AIDSVAX B-EIBA 04/2013 - 12/2009
3	EpitopesIBA 10/2022 - 01/2013
3	GP 140IBA 05/2022 - 04/2017
3	Complement System Proteins (Complement)IBA 01/2021 - 01/2017
3	Glycoproteins (Glycoprotein)IBA 01/2021 - 04/2015
3	env Gene ProductsIBA 11/2019 - 01/2012
3	EnzymesIBA 03/2019 - 11/2002
3	Peptides (Polypeptides)IBA 01/2019 - 01/2013
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2018 - 01/2017
3	Monoclonal AntibodiesIBA 02/2016 - 08/2015
2	Nucleic AcidsIBA 11/2023 - 06/2016
2	Combined VaccinesIBA 11/2023 - 01/2023
2	Dihydrotachysterol (AT 10)IBA 01/2023 - 01/2022
2	Viral RNAIBA 01/2023 - 11/2021
2	Ad26COVS1IBA 01/2022 - 10/2021
2	Polysaccharides (Glycans)IBA 10/2021 - 01/2016
2	ORALIT (ORS)IBA 07/2021 - 01/2013
2	Indicators and Reagents (Reagents)IBA 01/2020 - 01/2014
2	ImmunosorbentsIBA 03/2019 - 11/2002
2	ChemokinesIBA 01/2018 - 01/2018
2	Immunoglobulin M (IgM)IBA 12/2017 - 09/2016
2	Lipopolysaccharide ReceptorsIBA 01/2017 - 04/2011
2	Fatty Acid-Binding ProteinsIBA 01/2017 - 05/2016
2	HIV AntibodiesIBA 06/2016 - 01/2015
2	HLA-B Antigens (HLA-B)IBA 01/2016 - 05/2011
2	Viral DNAIBA 01/2016 - 05/2015
2	erdosteineIBA 01/2014 - 07/2012
1	Complex MixturesIBA 04/2024
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2023
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2023
1	DNA VaccinesIBA 01/2023
1	HLA Antigens (Human Leukocyte Antigens)IBA 10/2022
1	vesatolimodIBA 05/2022
1	aluminum sulfate (alum)IBA 05/2022
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2022
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 10/2021
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 01/2021
1	Illicit Drugs (Recreational Drugs)IBA 01/2021
1	Protective AgentsIBA 01/2021
1	N 556IBA 01/2021
1	IntegrinsIBA 12/2020
1	Chemokine ReceptorsIBA 12/2020
1	Ribosomal DNA (rDNA)IBA 12/2020
1	Histone Deacetylase InhibitorsIBA 09/2020
1	Vorinostat FDA Link 09/2020
1	A-Form DNA (A-DNA)IBA 11/2019
1	fas Receptor (CD95 Antigen)IBA 01/2019
1	dolutegravirIBA 01/2019
1	CD40 Ligand (CD40L)IBA 12/2018
1	Tenofovir (Viread)FDA Link 01/2018

Therapy/Procedure

19	Therapeutics 04/2024 - 01/2014
19	Art Therapy 11/2023 - 08/2014
4	Condoms (Condom) 01/2021 - 01/2014
4	Aftercare (After-Treatment) 10/2020 - 01/2016
3	Highly Active Antiretroviral Therapy (HAART) 11/2019 - 01/2016
1	Contraindications 10/2023